RxDoctor Payments Data

Md Karim, MD

Internal Medicine · Erwin, NCNPI 1821329665

Payments from drug & device makers

$2,145in general payments, 2019–2025

Across 80 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$994
  • Lilly USA, LLC$249
  • AbbVie$212
  • Amgen$125
  • Corcept Therapeutics$114
  • Novartis$97
  • plus $355 from 9 others

What the payments were for

  • Food & beverage$2,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,145 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$325,932
Medicare patients
312
Services billed
6,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,701
Albuterol Sulfate HfaAlbuterol Sulfate30$806
Bumetanide14$467
Montelukast Sodium73$449
Potassium Chloride22$347
Metoprolol Succinate27$282
Metolazone14$265
Omeprazole26$166
Venlafaxine Hcl ErVenlafaxine Hcl14$160
Ketoconazole11$137
Buspirone Hcl17$127
Amlodipine Besylate24$93
Tizanidine Hcl14$92
Duloxetine Hcl15$86
Rosuvastatin Calcium19$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$76$12,70114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Erwin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →